Compare AU
Compare VLUE vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the MSCI International Value 250 (ex AUS) (VLUE) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VLUE | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 25 | 81 |
Median incremental investment | $1,000.00 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,205.20 | $1,413.72 |
Average age group | > 35 | > 35 |
Key Summary
VLUE | CURE | |
|---|---|---|
Strategy | VLUE.AX was created on 2021-03-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. VLUE.AX gives investors a diversified portfolio of 250 international developed market large- and mid-cap companies, with high value scores as calculated by MSCI at each rebalance. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Cisco Systems Inc (3.69 %) International Business Machines Corp (2.42 %) Qualcomm Inc (2.38 %) | Moderna Inc (2.59 %) Neurocrine Biosciences Inc (2.50 %) AbbVie Inc (2.40 %) |
Top 3 industries | Information Technology (49.14 %) Communication Services (25.81 %) Consumer Discretionary (11.04 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (44.95 %) Japan (21.76 %) United Kingdom of Great Britain and Northern Ireland (7.35 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.4 % | 0.45 % |
Key Summary
VLUE | CURE | |
|---|---|---|
Issuer | VanEck | Global X |
Tracking index | MSCI World ex Australia Index - AUD - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.45 % |
Price | $26.71 | $50.49 |
Size | $291.723 million | $36.961 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.00 % | 4.24 % |
Market | ASX | ASX |
First listed date | 09/03/2021 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VLUE | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 25 | 81 |
Median incremental investment | $1,000.00 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,205.20 | $1,413.72 |
Average age group | > 35 | > 35 |
Pros and Cons
VLUE | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VLUE | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |